EPS for Agile Therapeutics, Inc. (AGRX) Expected At $-0.25

February 15, 2018 - By Vivian Currie

 EPS for Agile Therapeutics, Inc. (AGRX) Expected At $ 0.25
Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.74, from 0.61 in 2017Q2. It improved, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.
Caxton reported 1.82M shares. Blackrock, a New York-based fund reported 108,891 shares. Dimensional Fund Advsr Ltd Partnership has 95,820 shares for 0% of their portfolio. Art Advsr Limited Liability, a New York-based fund reported 15,512 shares. Franklin Res has 2.77M shares. Vanguard owns 670,032 shares for 0% of their portfolio. Geode Capital Mgmt reported 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Endurant L P stated it has 0.6% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Virtu Ltd Liability Com reported 83,806 shares stake. Janney Montgomery Scott Ltd Com stated it has 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Cormorant Asset Mgmt Ltd has 1.25M shares. 20,800 are owned by Barclays Public Limited Company. Acadian Asset Mngmt Ltd Liability Corporation holds 0% or 12,725 shares. Millennium Mngmt Limited Liability Company, a New York-based fund reported 143,326 shares. Jpmorgan Chase & Com owns 112,773 shares.

Analysts expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to report $-0.25 EPS on March, 14.They anticipate $0.04 EPS change or 13.79 % from last quarter’s $-0.29 EPS. After having $-0.22 EPS previously, Agile Therapeutics, Inc.’s analysts see 13.64 % EPS growth. The stock decreased 1.08% or $0.04 during the last trading session, reaching $3.66. About 68,415 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 15, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, October 10 with “Buy”. The stock has “Hold” rating by William Blair on Friday, December 22. The firm has “Buy” rating given on Friday, December 22 by Noble Financial. On Monday, October 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The company was downgraded on Tuesday, December 26 by William Blair. As per Monday, November 20, the company rating was maintained by Cantor Fitzgerald. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) earned “Buy” rating by Cantor Fitzgerald on Friday, January 8. Cantor Fitzgerald maintained it with “Buy” rating and $8.0 target in Monday, November 6 report. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Friday, December 22 with “Buy” rating. The firm earned “Hold” rating on Friday, December 22 by Janney Capital.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $125.12 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More important recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Prnewswire.com which released: “Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla …” on October 31, 2017, also Seekingalpha.com published article titled: “Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look”, Seekingalpha.com published: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” on September 05, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) was released by: Globenewswire.com and their article: “Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual …” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.